Trial Profile
Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results (n= 18) assessing safety and efficacy of the combination of pembrolizumab and mifepristone in advanced HER2-negative breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 26 Apr 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2025.
- 26 Apr 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2025.